Artgen Biotech (MOEX: ABIO), a biotechnology company with a portfolio of innovative solutions for the diagnosis, treatment, and prevention of socially significant diseases, has released its results for the full year 2025, prepared in accordance with Russian Accounting Standards (RAS).
In line with its updated development strategy for 2024–2026, Artgen Biotech generates revenue from dividends received from its subsidiary companies.
Net profit of Artgen Biotech in 2025 increased by 14% compared to the previous year, reaching 303.6 million rubles. The growth in net profit is primarily attributable to higher dividend income from subsidiaries and a positive balance of other income and expenses.
Artgen Biotech's development results will be presented alongside the consolidated IFRS financial statements for 2025, which provide the most complete and reliable picture of the Group's financial position. The release of the IFRS statements is scheduled for April 28, 2026.
Key Indicators of P&L Statement
|
RUB, thousands |
January - December 2025 |
January - December 2024 |
% change |
|
Revenue |
361 435 |
119 861 |
201,5% |
|
Cost of sales |
(11 306) |
(53 561) |
-78,9% |
|
Gross profit (loss) |
350 129 |
66 300 |
428,1% |
|
Commercial expenses |
- |
(16 185) |
-100% |
|
Management expenses |
(114 665) |
(97 320) |
17,8% |
|
Profit (loss) from sales |
235 464 |
(47 205) |
598,8% |
|
Income from participation in other entities |
- |
322 606 |
-100% |
|
Interest receivable |
73 581 |
66 039 |
11,4% |
|
Interest payable |
(41 390) |
(38 082) |
8,7% |
|
Other income (expenses), net |
12 420 |
(59 561) |
120,9% |
|
Net profit (loss) |
303 605 |
265 454 |
14,4% |
|
Net profit, % |
84% |
221,47% |
- |
|
RUB, thousands |
December 31, 2025 |
December 31, 2024 |
% change |
|
ASSETS |
|||
|
Financial investments |
4 684 107 |
4 447 400 |
5,3% |
|
Total non-current assets |
4 869 320 |
4 633 886 |
5,1% |
|
Accounts receivable |
209 162 |
260 781 |
-19,8% |
|
Financial investments |
249 437 |
283 397 |
-12% |
|
Cash and cash equivalents |
268 685 |
99 917 |
168,9% |
|
Total current assets |
730 316 |
674 467 |
8,3% |
|
TOTAL ASSETS |
5 599 636 |
5 308 353 |
5,5% |
|
LIABILITIES |
|||
|
Revaluation of non-current assets |
2 404 403 |
2 767 929 |
-13,1% |
|
Undistributed profits (outstanding loss) |
1 309 445 |
1 005 581 |
30,2% |
|
Total capital and reserves |
4 803 751 |
4 868 296 |
-1,3% |
|
Borrowed funds |
300 000 |
375 871 |
-20,2% |
|
Other liabilities |
3 510 |
16 005 |
-78,1% |
|
Total long-term liabilities |
307 828 |
399 717 |
-23% |
|
Borrowed funds |
470 529 |
- |
- |
|
Accounts payable |
16 597 |
36 592 |
-54,6% |
|
Total current liabilities |
488 057 |
40 341 |
1109,8% |
|
TOTAL LIABILITIES |
5 599 636 |
5 308 353 |
5,5% |
Artgen Biotech is a biotechnology company with a portfolio of innovative platform R&D projects, bringing them into practical healthcare. The Artgen Biotech Group comprises companies at various stages of development — from the seed stage to early growth and maturity — as well as companies that form an ecosystem for accelerating biotech R&D within the Group.
The unaudited non-consolidated financial statements of Artgen PJSC for 2025 under RAS are available on the corporate website in the "Investors" section (RAS Financial Statements).